# Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC

> **NCT03952325** · PHASE2 · TERMINATED · sponsor: **Odonate Therapeutics, Inc.** · enrollment: 294 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Tesetaxel
- **DRUG:** Tesetaxel
- **DRUG:** Tesetaxel
- **DRUG:** Nivolumab
- **DRUG:** Pembrolizumab
- **DRUG:** Atezolizumab
- **DRUG:** Tesetaxel

## Key facts

- **NCT ID:** NCT03952325
- **Lead sponsor:** Odonate Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-09
- **Primary completion:** 2021-06-23
- **Final completion:** 2021-06-23
- **Target enrollment:** 294 (ACTUAL)
- **Why stopped:** The Sponsor has discontinued the development of tesetaxel
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03952325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03952325, "Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03952325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*